SCHEMBL2433034

SCHEMBL2433034

O=C(Cc1ccc2nc(-c3cccnc3)oc2c1)C(F)(O[C@H]1CC[C@H](C(=O)O)CC1)N1CCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 8/20 0.49
ITGA4 P13612 8/20 0.49
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 3/20 0.44
NPC1 O15118 2/20 0.44
MAPK1 P28482 1/20 0.44
S1PR1 P21453 4/20 0.41
S1PR3 Q99500 3/20 0.41
ACSL1 P33121 1/20 0.41
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
ESR1 P03372 1/20 0.39
POLB P06746 1/20 0.39
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2433525 0.92 NPC1 (0.47) ITGB1ITGA4KDM4EALDH1A1NPC1
SCHEMBL2433631 0.84 ITGB1 (0.61) ITGB1ITGA4S1PR1S1PR3ACSL1
SCHEMBL2431939 0.84 ITGB1 (0.62) ITGB1ITGA4S1PR1S1PR3ACSL1
SCHEMBL2432187 0.84 ITGB1 (0.44) ITGB1ITGA4S1PR1S1PR3ACSL1
SCHEMBL2432184 0.84 ITGB1 (0.44) ITGB1ITGA4S1PR1S1PR3ACSL1
SCHEMBL2440038 0.79 ITGB1 (0.41) ITGB1ITGA4S1PR1S1PR3ACSL1
SCHEMBL2429140 0.79 ITGA4 (0.52) ITGB1ITGA4NPC1RAB9A
SCHEMBL2434329 0.78 ITGB1 (0.64) ITGB1ITGA4S1PR1S1PR3PDCD1
SCHEMBL2436546 0.78 ITGB1 (0.63) ITGB1ITGA4S1PR1S1PR3PDCD1
SCHEMBL2436543 0.78 ITGB1 (0.63) ITGB1ITGA4S1PR1S1PR3PDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 ITGB1 5/4885ITGA4 4/4885KDM4E 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.